The 340B Drug Pricing Program continues to expand at a rapid pace, reshaping the pharmaceutical landscape and challenging manufacturers to adapt. In 2023 alone, the program grew by over 16%, surpassing both non-340B growth (11%) and its own previous year’s growth rate (12%). With total volume now exceeding $124 billion, the need for clear, actionable insights into 340B dynamics has never been greater.

Enter the IQVIA 340B Dynamics Dashboard, a powerful, interactive solution designed to help manufacturers, brand teams, and market access leaders understand and respond to the evolving 340B environment.

Why the 340B program demands attention

Despite its growing impact, the 340B program remains poorly understood by many stakeholders. Often compared to an iceberg, much of its influence lies beneath the surface, hidden in complex policies, opaque data, and unforeseen consequences like duplicate discounts and copay assistance disruptions.

Three core challenges facing manufacturers:

1. In-depth understanding
   Many senior leaders are unaware of the program’s full impact on gross-to-net (GTN) performance. Insights teams are often under-resourced and lack the tools to answer critical business questions.
2. Limited visibility
   Most manufacturers rely solely on chargeback data, which lacks the broader context needed to understand brand performance, competitive benchmarks, and the effects of policy changes.
3. Retrospective insights
   Current analytics only reflect past exposure. With states continuing to pass laws expanding contract pharmacy access, manufacturers are being re-exposed to 340B volume without the foresight to prepare.

IQVIA 340B insights

The IQVIA 340B Dynamics Dashboard is designed to cut through the noise and deliver insights, not just data. It provides a unified, visual, and interactive experience that empowers stakeholders across functions to make informed decisions.

The dashboard is structured to answer key questions across four main dimensions:

Market-level trends

• What are the key 340B performance metrics?
• How has the program grown over time?
• How are sales distributed across channels?
• Which disease areas are driving growth?

Brand-level trends

• How have brand sales evolved?
• Which channels are driving year-over-year changes?
• How is 340B exposure shifting across distribution points?

State-level policy impact

• What is the effect of contract pharmacy laws on brand exposure?
• What risks do new state laws pose to your portfolio?

Brand vs. brand comparisons

• How does your brand stack up against competitors?
• What are the exposure trends across similar therapeutic areas?

Real-world applications

The dashboard isn’t just a reporting tool—it’s a strategic asset. It supports a wide range of initiatives, including:

• Educating internal teams on 340B dynamics
• Enhancing GTN and contract operations business cases
• Informing brand-level market access strategies
• Guiding advocacy and policy engagement
• Supporting new product launch planning

Why it matters

Understanding the 340B program is no longer optional. With state legislation expanding access, operational strategies evolving, and pricing models shifting (especially in the insulin market), manufacturers must be proactive. The IQVIA 340B Dynamics Dashboard offers a clear path forward, equipping teams with the insights they need to navigate uncertainty and drive smarter decisions.